Quantcast

Latest CD4 Stories

2014-05-30 08:24:46

First Clinical Application of Genome Editing Technology in Hematopoietic Stem/Progenitor Cells RICHMOND, Calif., May 30, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN)...

2014-05-02 10:06:07

Enzyme's double-edged sword may soon be sheathed Johns Hopkins biochemists have figured out what is needed to activate and sustain the virus-fighting activity of an enzyme found in CD4+ T cells, the human immune cells infected by HIV. The discovery could launch a more effective strategy for preventing the spread of HIV in the body with drugs targeting this enzyme, they say. A summary of their work was published online on April 21 in the journal Proceedings of the National Academy of...

2014-04-24 08:34:57

Easy-to-use CD4 analysis platform tailored to meet the needs of resource-limited settings SAN JOSE, Calif., April 24, 2014 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD FACSPresto(TM) Near Patient CD4 Counter system that provides absolute and percentage results of CD4 T lymphocytes and hemoglobin (Hb) concentration in whole blood samples to stage and...

2014-03-06 12:28:29

Company Outlines Future Plans for HIV "Functional Cure" RICHMOND, Calif., March 6, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of data from its SB-728-T program to develop a 'functional cure' for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections (CROI 2014). The conference is being held in Boston from March 3 to 6, 2014. Data from an earlier Phase 1 clinical study in this program were also published in the March 6,...

2014-03-05 16:26:40

Treatment with Sangamo's ZFN- Modified T-cells (SB-728-T) Provides Functional Control of HIV without Antiretroviral Drugs RICHMOND, Calif., March 5, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication in the New England Journal of Medicine of the first clinical study of its proprietary zinc finger nuclease (ZFN)-based genome editing technology in humans. Data from the study, carried out in HIV-positive subjects, demonstrate that the T-cell...

2014-02-18 09:01:07

A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes. In the Immune Tolerance Network's (ITN) HALT-MS study, 24 patients with relapsing, remitting multiple sclerosis received high-dose immunosuppression followed by a transplant of their own stem cells, called an autologous stem cell transplant, to potentially reprogram the immune system so that...

2014-02-04 11:58:44

Researchers use a naturally occurring HIV variant to trace a T cell lineage for 17 years WHAT: A team of researchers has reported a novel method for tracking CD4+ T cells in people infected with HIV. CD4+ T cells are critical for immune defense against an array of pathogens and are a primary target of HIV. In the study, researchers used a unique, replication-incompetent (defective) form of HIV identified in a patient in the early 1990s. The defective virus had integrated into the genome...

2014-02-04 11:29:24

Nearly half of HIV-infected teenagers and young adults forego timely treatment, delaying care until their disease has advanced, which puts them at risk for dangerous infections and long-term complications, according to a study led by the Johns Hopkins Children's Center. The researchers say their findings, published Feb. 3 in JAMA Pediatrics, are particularly troubling in light of mounting evidence that starting treatment as early as possible can go long way toward keeping the virus in...

2014-01-09 08:27:16

PITTSBURGH, Jan. 9, 2014 /PRNewswire/ -- Mylan, Inc. (Nasdaq: MYL) today announced that Zyomyx's MyT4(TM) point-of-care CD4 diagnostic test has received the CE Certificate of Conformity in the European Union, an important step toward launching this innovative test and expanding access to affordable, accessible and reliable diagnostics for people living with HIV globally. As a result, the MyT4(TM) CD4 test can now bear the CE Mark, which demonstrates that the MyT4(TM) CD4 test complies...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related